Meribank Biotech Co (ROCO:4724) COGS-to-Revenue : 0.40 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co COGS-to-Revenue?

Meribank Biotech Co's Cost of Goods Sold for the six months ended in Dec. 2023 was NT$52.0 Mil. Its Revenue for the six months ended in Dec. 2023 was NT$131.3 Mil.

Meribank Biotech Co's COGS to Revenue for the six months ended in Dec. 2023 was 0.40.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Meribank Biotech Co's Gross Margin % for the six months ended in Dec. 2023 was 60.39%.

Meribank Biotech Co COGS-to-Revenue Historical Data

The historical data trend for Meribank Biotech Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co COGS-to-Revenue Chart

Meribank Biotech Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.42

0.41

0.45

0.47

0.41

Meribank Biotech Co Semi-Annual Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial							0.47	0.45	0.49	0.42	0.40

Meribank Biotech Co COGS-to-Revenue Calculation

Meribank Biotech Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	95.472	/	234.342
	=	0.41

Meribank Biotech Co's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	51.995	/	131.28
	=	0.40

Meribank Biotech Co (ROCO:4724) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Meribank Biotech Co's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	51.995 / 131.28
	=	60.39 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Meribank Biotech Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Meribank Biotech Co (ROCO:4724) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493

Website

http://www.meribank.com.tw

Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co (ROCO:4724) Headlines

No Headlines